Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 50,422 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Clear all

Conditions: Lung Cancer, Metastatic Cancer
Interventions: Erlotinib plus Romidepsin (8 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis, (Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis; Combination Product
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Neoplasms
Interventions: LY353381, tamoxifen; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: Miami, Florida • Shreveport, Louisiana • Boston, Massachusetts + 1 more

Conditions: Adenoma and/or Adenocarcinoma, Adenoma
Interventions: 3-minute withdrawal time, 6-minute withdrawal time; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Palo Alto, California

Conditions: Multiple Myeloma
Interventions: Pamidronate, Thalidomide; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Lung Cancer
Interventions: cisplatin, irinotecan hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 8
States / cities: Millville, New Jersey • Mount Holly, New Jersey • Red Bank, New Jersey + 5 more

Conditions: Autism, Tuberous Sclerosis
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 4 Years to 18 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Neuroendocrine Tumor
Interventions: Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Triapine; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 25
States / cities: Duarte, California • Irvine, California • Orange, California + 19 more

Conditions: Prostate Cancer, Male Erectile Disorder, Stage I Prostate Cancer, Stage II Prostate Cancer
Interventions: sildenafil citrate, alprostadil, robotic-assisted laparoscopic surgery, quality-of-life assessment, questionnaire administration; Drug · Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Duarte, California

Conditions: Epithelial Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions: Birinapant (TL32711); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma
Interventions: filgrastim, rituximab, busulfan, cisplatin, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methylprednisolone, prednisone, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, positron emission tomography, fludeoxyglucose F 18, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Breast Cancer
Interventions: Verteporfin, Continuous Low-Irradiance Photodynamic Therapy (CLIPT); Drug · Device
Lead sponsor: Rogers Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lymphoma, Small Intestine Cancer
Interventions: vorinostat, Correlative studies; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Metastatic Non Small Cell Lung Cancer
Interventions: Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 36
States / cities: Daphne, Alabama • Chandler, Arizona • Prescott Valley, Arizona + 32 more

Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Alemtuzumab, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Etoposide Phosphate, Filgrastim, Fludarabine Phosphate, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis, Leucovorin Calcium, Melphalan, Mercaptopurine, Methotrexate, Pegfilgrastim, Pharmacological Study, Tacrolimus, Vincristine Sulfate; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 101
States / cities: Palo Alto, California • Aurora, Colorado • Boulder, Colorado + 68 more

Conditions: Leukemia, Lymphoma
Interventions: Platelet Transfusion; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain Cancer
Interventions: 18F-FSPG; Drug
Lead sponsor: Lantheus Biosciences Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma
Interventions: ITIL-306; Biological
Lead sponsor: Instil Bio; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: St Louis, Missouri • New York, New York

Conditions: Lung Cancer, SCLC
Interventions: Nivolumab, Plinabulin, Ipilimumab; Drug
Lead sponsor: Salma Sabbour; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more

Conditions: Pancreatic Cancer
Interventions: Proton radiation and chemotherapy; Radiation
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Oral Squamous Cell Carcinoma (OSCC)
Interventions: Olaparib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Breast Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: University of Southern California; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Appendiceal Mucinous Neoplasm, Pseudomyxoma Peritonei
Interventions: Metformin; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Orange, California

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Placebo, Venetoclax, Cytarabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 6
States / cities: Tampa, Florida • Louisville, Kentucky • Pittsburgh, Pennsylvania + 3 more

Conditions: Liver Cancer
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2024
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Comparison of Adenoma Detection Miss Rates at Colonoscopy Associated With Different Withdrawal Times

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Studies of Autistic Patients: Gene Networks and Clinical Subtypes

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

ED Recovery in Men Age </=65 Treated With Bilateral Nerve Sparing Robotic Assisted Prostatectomy for Prostate Cancer

Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets

PET Imaging of Intracranial Cancers With 18F-FSPG

ITIL-306 in Advanced Solid Tumors

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Proton Radiation for Resectable Carcinoma of the Pancreas

A Dye for the Detection of Cancer of the Tongue and Mouth

Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer

Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma